Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
Pfizer (NYSE: PFE) reported positive topline Phase 2b VESPER-3 results for PF’3944, an ultra-long-acting injectable GLP-1 RA, showing up to 12.3% placebo-adjusted mean weight loss at week 28 with a monthly maintenance regimen after weekly titration. The primary endpoint was met (P<0.001) across four dose arms.
PF’3944 maintained a tolerable safety profile through week 28; Pfizer plans >20 obesity trials in 2026, including 10 Phase 3 studies for PF’3944 and a planned higher 9.6 mg monthly dose in Phase 3.
Pfizer (NYSE: PFE) reported Cohort 3 results from the BREAKWATER trial evaluating BRAFTOVI (encorafenib) plus cetuximab and FOLFIRI in previously untreated BRAF V600E-mutant metastatic colorectal cancer. The regimen improved confirmed objective response rate to 64.4% versus 39.2% for FOLFIRI with or without bevacizumab (odds ratio 2.76, p=0.001). Estimated median duration of response was not estimable for the investigational arm; 57.4% of responders on the investigational arm had responses ≥6 months. Overall survival was analyzed descriptively (HR 0.49, 95% CI 0.24–1.03; ~10-month follow-up). No new safety signals identified; 8.5% discontinued BRAFTOVI for adverse reactions. Trial completion estimated 2027.
Summary not available.
Pfizer (NYSE: PFE) will webcast a discussion with Chairman and CEO Albert Bourla at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. PST. Registration and access details are available at www.pfizer.com/investors beginning January 5, 2026. A transcript and replay will be posted within 24 hours and remain accessible for at least 90 days.
The webcast may include forward-looking statements about financial performance, pipeline, and strategy; risk disclosures are referenced to Pfizer’s SEC reports.
Pfizer (NYSE: PFE) invites investors and the public to a webcasted conference call with analysts at 10:00 a.m. EST on Tuesday, February 3, 2026 to discuss its Fourth Quarter and Full Year 2025 Performance Report, which will be issued that morning. Registration and webcast access instructions are available at www.pfizer.com/investors. Dial-in numbers: 800-456-4352 (U.S./Canada) or 785-424-1086 (international) using passcode 10856. A transcript and replay will be posted on the investor website within 24 hours and will be accessible for at least 90 days. Contact: IR@Pfizer.com.
Pfizer (NYSE: PFE) and Astellas announced positive topline results from an interim analysis of the Phase 3 EV-304 (KEYNOTE-B15) trial on Dec. 17, 2025.
The trial evaluated PADCEV (enfortumab vedotin) plus Keytruda (pembrolizumab) as neoadjuvant and adjuvant therapy versus standard cisplatin-based neoadjuvant chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). The study met its primary endpoint with clinically meaningful and statistically significant improvements in event-free survival (EFS) and also showed a statistically significant improvement in overall survival (OS) (key secondary) and in pathologic complete response (pCR). Safety was consistent with the known profile. Results will be presented at a medical meeting and discussed with global health authorities for potential regulatory filings.
Pfizer (NYSE:PFE) on December 16, 2025 reaffirmed full‑year 2025 adjusted diluted EPS guidance and revised 2025 revenue to approximately $62.0 billion, while providing full‑year 2026 guidance. Key 2026 guidance: revenues $59.5–$62.5 billion and adjusted diluted EPS $2.80–$3.00. Pfizer expects COVID‑19 product revenues of ~$5.0 billion in 2026 (about $1.5 billion lower than 2025) and an additional ~$1.5 billion negative impact from loss of exclusivity. 2026 adjusted SI&A and R&D combined are expected at $23.0–$25.0 billion, and the effective adjusted tax rate is expected to rise to ~15% from ~11% in 2025. A live webcast and call were scheduled for December 16, 2025 at 8:00 AM ET.
Pfizer (NYSE: PFE) announced its board approved a $0.43 per share quarterly cash dividend for first-quarter 2026. The dividend is payable March 6, 2026 to shareholders of record at the close of business on January 23, 2026. This payment will mark Pfizer's 349th consecutive quarterly dividend, continuing the company's long-running shareholder distribution record.
Pfizer (NYSE: PFE) reported Phase 3 HER2CLIMB-05 results showing TUKYSA (tucatinib) added to trastuzumab and pertuzumab as first-line maintenance reduced risk of progression or death by 35.9% (HR 0.641; 95% CI 0.514-0.799; p<0.0001) versus trastuzumab and pertuzumab alone.
Median progression-free survival was 24.9 months with TUKYSA vs 16.3 months with placebo, an extension of 8.6 months. PFS benefit was consistent across prespecified subgroups. Overall survival was not mature (≈20% of events) and showed a numerical trend favoring TUKYSA. Safety was generally consistent with known profiles but included a higher rate of asymptomatic Grade ≥3 liver transaminase elevations, typically manageable with dose changes or discontinuation. TUKYSA is not approved for first-line use; results will be discussed with regulators.
Fosun Pharma (PFE) subsidiary Yao Pharma and Pfizer (PFE) entered an exclusive global collaboration and license agreement on December 9, 2025.
Yao Pharma will complete a Phase 1 trial of oral small‑molecule GLP‑1R agonist YP05002 in Australia and grants Pfizer an exclusive worldwide license to develop, manufacture and commercialize YP05002 and related oral small‑molecule GLP‑1R agonists for all human and veterinary indications.
Financial terms include an upfront payment of $150 million, up to $1.935 billion in development/regulatory/commercial milestone payments, plus tiered royalties on sales.